texas oncology more breakthroughs. more victories

Share:

 
 

Habte Yimer, MD, Regarding the Lyra Trial in Newly Diagnosed Multiple Myeloma Presented at ASH 2018

Publication: Oncology Business Review
12/14/2018

Habte Yimer, hematologist and medical oncologist with Texas Oncology–Tyler, addresses the impact of Lyra, a Phase 2 study investigating daratumumab in newly diagnosed multiple myeloma patients.
Click here to watch the full story.

Related Physicians

Related Cancer Centers